Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1992 Jan;105(1):87–92. doi: 10.1111/j.1476-5381.1992.tb14215.x

Platelet-activating factor synthesis by peritoneal mast cells and its inhibition by two quinoline-based compounds.

C M Hogaboam 1, D Donigi-Gale 1, T S Shoupe 1, E Y Bissonnette 1, A D Befus 1, J L Wallace 1
PMCID: PMC1908618  PMID: 1596692

Abstract

1. Peritoneal mast cells from rat were co-incubated in vitro in a platelet aggregometer cuvette with washed rabbit platelets. In response to stimulation with calcium ionophore (A23187; 1-5 microM), the mast cells released a substance which stimulated the platelets to aggregate. These concentrations of ionophore did not stimulate platelet aggregation in the absence of mast cells, nor affect the responsiveness of the platelets to aggregation induced by thrombin or PAF. Release of a PAF-like substance was also observed in response to stimulation of the mast cells with antigen. 2. This pro-aggregatory activity is attributable to the release of PAF by the mast cells, since the activity could be abolished by preincubating the platelets with a specific PAF receptor antagonist (WEB 2086; 10 microM). Furthermore, the platelet-aggregating factor co-migrated with PAF on thin-layer chromatographs and could be abolished by incubation with phospholipase A2 (20 micrograms ml-1) or a specific antibody directed against PAF. 3. The release of PAF by peritoneal mast cells could be inhibited, in a concentration-dependent manner, by PF-5901 (IC50 of 3.9 microM) or Wy-50,295 (IC50 of 1.2 microM), two structurally similar compounds with inhibitory effects on leukotriene synthesis, as well as leukotriene D4 (LTD4) receptor antagonist properties. 4. Inhibition of PAF synthesis was not observed when the mast cells were incubated with a structurally unrelated 5-lipoxygenase inhibitor (A-64077), a structurally dissimilar inhibitor of 5-lipoxygenase activating protein (MK-886) or with a structurally related LTD4 receptor antagonist (MK-571) which lacks inhibitory effects on leukotriene synthesis, each at concentrations of up to 100 microM.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
87

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Befus A. D., Bienenstock J. Immunologically mediated intestinal mastocytosis in Nippostrongylus brasiliensis-infected rats. Immunology. 1979 Sep;38(1):95–101. [PMC free article] [PubMed] [Google Scholar]
  2. Bissonnette E. Y., Befus A. D. Inhibition of mast cell-mediated cytotoxicity by IFN-alpha/beta and -gamma. J Immunol. 1990 Nov 15;145(10):3385–3390. [PubMed] [Google Scholar]
  3. Braquet P., Touqui L., Shen T. Y., Vargaftig B. B. Perspectives in platelet-activating factor research. Pharmacol Rev. 1987 Jun;39(2):97–145. [PubMed] [Google Scholar]
  4. Casals-Stenzel J., Muacevic G., Weber K. H. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. J Pharmacol Exp Ther. 1987 Jun;241(3):974–981. [PubMed] [Google Scholar]
  5. Chand N., Diamantis W., Pillar J., Sofia R. D. Modulation of allergic and nonallergic histamine secretion by lipoxygenase inhibitors. Res Commun Chem Pathol Pharmacol. 1987 Jan;55(1):49–57. [PubMed] [Google Scholar]
  6. Evans J. F., Lévillé C., Mancini J. A., Prasit P., Thérien M., Zamboni R., Gauthier J. Y., Fortin R., Charleson P., MacIntyre D. E. 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors. Mol Pharmacol. 1991 Jul;40(1):22–27. [PubMed] [Google Scholar]
  7. Gordon J. R., Burd P. R., Galli S. J. Mast cells as a source of multifunctional cytokines. Immunol Today. 1990 Dec;11(12):458–464. doi: 10.1016/0167-5699(90)90176-a. [DOI] [PubMed] [Google Scholar]
  8. Heavey D. J., Ernst P. B., Stevens R. L., Befus A. D., Bienenstock J., Austen K. F. Generation of leukotriene C4, leukotriene B4, and prostaglandin D2 by immunologically activated rat intestinal mucosa mast cells. J Immunol. 1988 Mar 15;140(6):1953–1957. [PubMed] [Google Scholar]
  9. Joly F., Bessou G., Benveniste J., Ninio E. Ketotifen inhibits paf-acether biosynthesis and beta-hexosaminidase release in mouse mast cells stimulated with antigen. Eur J Pharmacol. 1987 Dec 1;144(2):133–139. doi: 10.1016/0014-2999(87)90511-5. [DOI] [PubMed] [Google Scholar]
  10. Jones T. R., Zamboni R., Belley M., Champion E., Charette L., Ford-Hutchinson A. W., Frenette R., Gauthier J. Y., Leger S., Masson P. Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol. 1989 Jan;67(1):17–28. doi: 10.1139/y89-004. [DOI] [PubMed] [Google Scholar]
  11. Laursen L. S., Naesdal J., Bukhave K., Lauritsen K., Rask-Madsen J. Selective 5-lipoxygenase inhibition in ulcerative colitis. Lancet. 1990 Mar 24;335(8691):683–685. doi: 10.1016/0140-6736(90)90803-d. [DOI] [PubMed] [Google Scholar]
  12. Lee T. D., Shanahan F., Miller H. R., Bienenstock J., Befus A. D. Intestinal mucosal mast cells: isolation from rat lamina propria and purification using unit gravity velocity sedimentation. Immunology. 1985 Aug;55(4):721–728. [PMC free article] [PubMed] [Google Scholar]
  13. Lynch J. M., Henson P. M. The intracellular retention of newly synthesized platelet-activating factor. J Immunol. 1986 Oct 15;137(8):2653–2661. [PubMed] [Google Scholar]
  14. Masini E., Giannella E., Bani-Sacchi T., Fantozzi R., Palmerani B., Mannaioni P. F. Histamine release from serosal mast cells by intermediate products of arachidonic acid metabolism. Agents Actions. 1987 Apr;20(3-4):202–205. doi: 10.1007/BF02074669. [DOI] [PubMed] [Google Scholar]
  15. Mencia-Huerta J. M., Lewis R. A., Razin E., Austen K. F. Antigen-initiated release of platelet-activating factor (PAF-acether) from mouse bone marrow-derived mast cells sensitized with monoclonal IgE. J Immunol. 1983 Dec;131(6):2958–2964. [PubMed] [Google Scholar]
  16. Musch M. W., Billah M. M., Siegel M. I. Antigen-and ionophore-stimulated synthesis of platelet-activating factor by the cloned mast cell line, MC9. Biochem Biophys Res Commun. 1987 May 14;144(3):1243–1250. doi: 10.1016/0006-291x(87)91444-6. [DOI] [PubMed] [Google Scholar]
  17. Parente L., Flower R. J. Hydrocortisone and 'macrocortin' inhibit the zymosan-induced release of lyso-PAF from rat peritoneal leucocytes. Life Sci. 1985 Apr 1;36(13):1225–1231. doi: 10.1016/0024-3205(85)90266-8. [DOI] [PubMed] [Google Scholar]
  18. Radomski M., Moncada S. An improved method for washing of human platelets with prostacyclin. Thromb Res. 1983 May 15;30(4):383–389. doi: 10.1016/0049-3848(83)90230-x. [DOI] [PubMed] [Google Scholar]
  19. Rouzer C. A., Ford-Hutchinson A. W., Morton H. E., Gillard J. W. MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. J Biol Chem. 1990 Jan 25;265(3):1436–1442. [PubMed] [Google Scholar]
  20. SHORE P. A., BURKHALTER A., COHN V. H., Jr A method for the fluorometric assay of histamine in tissues. J Pharmacol Exp Ther. 1959 Nov;127:182–186. [PubMed] [Google Scholar]
  21. Salvemini D., Masini E., Anggard E., Mannaioni P. F., Vane J. Synthesis of a nitric oxide-like factor from L-arginine by rat serosal mast cells: stimulation of guanylate cyclase and inhibition of platelet aggregation. Biochem Biophys Res Commun. 1990 Jun 15;169(2):596–601. doi: 10.1016/0006-291x(90)90372-t. [DOI] [PubMed] [Google Scholar]
  22. Schleimer R. P., MacGlashan D. W., Jr, Peters S. P., Pinckard R. N., Adkinson N. F., Jr, Lichtenstein L. M. Characterization of inflammatory mediator release from purified human lung mast cells. Am Rev Respir Dis. 1986 Apr;133(4):614–617. doi: 10.1164/arrd.1986.133.4.614. [DOI] [PubMed] [Google Scholar]
  23. Triggiani M., Hubbard W. C., Chilton F. H. Synthesis of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine by an enriched preparation of the human lung mast cell. J Immunol. 1990 Jun 15;144(12):4773–4780. [PubMed] [Google Scholar]
  24. Van Inwegen R. G., Khandwala A., Gordon R., Sonnino P., Coutts S., Jolly S. REV 5901: an orally effective peptidoleukotriene antagonist, detailed biochemical/pharmacological profile. J Pharmacol Exp Ther. 1987 Apr;241(1):117–124. [PubMed] [Google Scholar]
  25. Warner J. A., Lichtenstein L. M., MacGlashan D. W., Jr Effects of a specific inhibitor of the 5-lipoxygenase pathway on mediator release from human basophils and mast cells. J Pharmacol Exp Ther. 1988 Oct;247(1):218–222. [PubMed] [Google Scholar]
  26. Zimmerman G. A., McIntyre T. M., Mehra M., Prescott S. M. Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion. J Cell Biol. 1990 Feb;110(2):529–540. doi: 10.1083/jcb.110.2.529. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES